| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthesized peptide derived from human CBR1 was used as the immunogen for the CBR1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CBR1 Antibody / Carbonyl reductase 1 is a anti-CBR1 Rabbit antibody Recombinant Rabbit Monoclonal clone 30C98 supplied in Liquid format. Recommended for workflows such as Western blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF) with listed reactivity in Human. Reported localization: Cytoplasm.
Key elements and design rationale
- Target: CBR1
- Antibody details: Rabbit, Recombinant Rabbit Monoclonal, clone 30C98, isotype Rabbit IgG
- Format: Liquid
- Applications (as listed): WB, IHC, ICC, IF
Biological background
Carbonyl reductase 1 contributes to the metabolism of anthracycline drugs such as doxorubicin, converting them to less active alcohol metabolites. While this reduces anticancer activity, it also influences drug toxicity, particularly cardiotoxicity. Research with CBR1 antibody has been central to understanding interindividual variability in anthracycline metabolism and its impact on therapeutic outcomes. CBR1 also reduces prostaglandins and quinones, helping regulate inflammatory responses and oxidative stress signaling.
CBR1 has been linked to cancer, cardiovascular disease, and neurodegeneration. Overexpression has been reported in several tumors, where it may promote resistance to chemotherapy. Conversely, genetic polymorphisms in the CBR1 gene influence enzymatic activity and alter susceptibility to drug side effects. Using CBR1 antibody, researchers have demonstrated its tissue specific expression, with high levels in liver, kidney, and heart, reflecting its role in systemic detoxification. These findings underscore the enzyme's dual role in both protecting tissues and modulating pharmacological efficacy.
CBR1 antibody is applicable in western blotting, immunohistochemistry, and enzymatic activity assays. Western blotting demonstrates isoform expression across tissues, while immunohistochemistry reveals cytosolic distribution. Activity based assays combined with CBR1 antibody confirm enzyme function and response to inhibitors. These approaches allow detailed mapping of metabolic pathways influenced by Carbonyl reductase 1.
By providing validated CBR1 antibody reagents,
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunofluorescence: visualize subcellular distribution and cell-to-cell heterogeneity.
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Monoclonal antibodies provide a defined epitope recognition profile that can support consistent comparisons across experiments.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
